MCTANasdaqServices-Misc Health & Allied Services, NEC

Charming Medical Ltd

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 30, 2026

$29.36+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Charming Medical Ltd balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31
Cash & Equivalents	4.70	0.82	2.10	1.93
Cash & Short-Term Investments	4.70	0.82	2.10	1.93
Receivables	0.20	0.40	–	–
Inventory	0.03	0.03	–	–
Total Current Assets	8.17	3.37	–	–
Property, Plant & Equipment	0.61	0.50	–	–
Gross Property, Plant & Equipment	1.45	1.38	–	–
Accumulated Depreciation	-0.84	-0.88	–	–
Operating Lease Right-of-Use Assets	0.72	0.71	–	–
Deferred Tax Assets	0.01	0.08	–	–
Total Assets	9.87	5.36	–	–
Accounts Payable	0.42	0.25	–	–
Short-Term Debt	0.19	0.31	–	–
Current Debt	0.19	0.31	–	–
Current Portion of Leases	0.37	0.47	–	–
Current Income Taxes Payable	0.31	0.22	–	–
Deferred Revenue (Current)	3.05	3.46	4.50	–
Other Current Liabilities	0.01	0.21	–	–
Total Current Liabilities	4.33	4.95	–	–
Long-Term Leases	0.36	0.26	–	–
Operating Lease Liabilities	0.72	0.73	–	–
Total Liabilities	4.69	5.31	–	–
Total Debt	0.19	0.31	–	–
Additional Paid-In Capital	5.10	0.31	–	–
Retained Earnings	0.10	0.12	–	–
Comprehensive Income & Other	-0.01	0.00	–	–
Shareholders' Equity	5.18	0.05	–	–
Total Equity	5.18	0.05	-1.15	-1.27
Total Liabilities & Equity	9.87	5.36	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin: 99.3%
Operating margin: -0.6%
Net margin: -0.5%
Return on equity, FY2026: -0.9%

Financial strength

Current ratio: 1.89
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 108.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –